Reactive arthritis primary prevention

Jump to navigation Jump to search

Reactive arthritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Reactive arthritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Reactive arthritis primary prevention On the Web

Most recent articles

Most cited articles

Review articles

Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Reactive arthritis primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Reactive arthritis primary prevention

CDC on Reactive arthritis primary prevention

Reactive arthritis primary prevention in the news

Blogs onReactive arthritis primary prevention

Directions to Hospitals Treating Reactive arthritis

Risk calculators and risk factors forReactive arthritis primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Akshun Kalia M.B.B.S.[2]

Overview

Effective measures for the primary prevention of reactive arthritis include early treatment of GI or GU infections, educating patients about association of GI and GU infection with reactive arthritis and use of barrier methods such as condoms can prevent spread of sexually transmitted disease.

Primary Prevention

Effective measures for the primary prevention of reactive arthritis include:[1]

References

  1. Colmegna I, Cuchacovich R, Espinoza LR (April 2004). "HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations". Clin. Microbiol. Rev. 17 (2): 348–69. PMC 387405. PMID 15084505.


Template:WikiDoc Sources